Sun Pharma reports profit dip due to Organon acquisition charge, specialty sales rise
Միայն փաստեր

Sun Pharma reports profit dip due to Organon acquisition charge, specialty sales rise

Ամփոփում

Sun Pharmaceutical Industries' Q2 net profit fell to 19.89 billion rupees, impacted by a one-time charge linked to its planned Organon purchase, while specialty drug sales grew 6.9%.

India's leading drugmaker by revenue posted a consolidated net profit of 19.89 billion rupees ($209 million) for the quarter ended September 30, down from 31.18 billion rupees a year earlier. The decline reflects a one-time charge of 12.69 billion rupees tied to costs associated with its planned acquisition of Organon and provisions related to India's labour code framework. Excluding the charge, profit rose 6.3% to 44.28 billion rupees.

Revenue increased nearly 12% to 161.99 billion rupees, beating analysts' average estimate of 158.25 billion rupees. Specialty drug sales, which the company is expanding to offset pressure in the U.S. market, grew 6.9% to $356 million, representing 21.1% of total sales. Growth was driven by a 17.3% rise in Indian sales, the firm's largest market, while U.S. sales fell 8.2%.

Following the earnings release, Sun Pharma's shares rose 4.2% to 1,835 rupees.

Աղբյուր

Reuters

Շարունակեք կարդալ — անվճար

Ստեղծեք անվճար հաշիվ՝ նորություններին հետևելու համար։ Քարտ չի պահանջվում։